Open innovation, open access platforms, and multi-party collaborations are generating creative business models for bringing to market new medicines that respond to unmet medical needs worldwide. Together, industry, research centers, non-profits, global agencies, venture capital community, consultants, and service providers are laying the foundations of a new collaborative biopharma ecosystem to translate early innovation into meaningful therapeutics. This session’s panel discussion will examine recent developments for accelerating drug innovation and raising the prospects for success.
- Explain why drug innovation translation to meaningful therapeutics requires collaboration among many business, research, translational, and financial partners
- Foster and promote collaborative environments across the biopharma sector
- Demonstrate success of collaborative models in drug innovation with examples
Ability Level: Advanced
Session ID: 2502